Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...

Heart failure has historically been irreversible, but the outcome of a new study suggests that could someday change. At the University of Utah, scientists used a new gene therapy that was shown to ...

University of California San Diego-led team has discovered that restoring a key cardiac protein called connexin‑43 in a mouse ...

Maintaining a stable heartbeat is critical for survival. Your heart must constantly adapt its output to meet changing demands ...

Scientists have identified a key reason why more than half of people with chronic kidney disease eventually die from heart-related conditions. New evidence shows that damaged kidneys release a ...

The brain and vagus nerve play a key role in exacerbating tissue damage after a heart attack, but there are ways to block it.

Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...

Ifetroban significantly improved LVEF in DMD patients, showing a 5.4% improvement compared with propensity-matched natural history controls, with high-dose treatment yielding the most benefit. The ...

Lower cardiac output has been tied to poorer cerebral blood flow (CBF) in the temporal lobes of older adults without heart failure, a finding that adds to a growing body of research linking heart ...

Heart attack symptoms in women can differ from the classic warning signs portrayed in men. Women may notice symptoms such as shortness of breath, nausea or overwhelming ...

Your feet might be telling you more about your heart than you realize. While seemingly unrelated, mounting evidence suggests that foot discomfort may serve as an early warning system for ...